psoriatic — TargetMol Chemicals

Cat No.	Product Name	Synonyms	Targets
T1068	Dithranol	1,8,9-trihydroxyanthracene,cignoline,Anthralin	Others , DNA/RNA Synthesis
	Dithranol (cignoline) is an anthracene derivative that disrupts MITOCHONDRIA function and structure and is used for the treatment of DERMATOSES, especially PSORIASIS. It may cause FOLLICULITIS.		Others , DNA/RNA Synthesis
T6668	SGC-CBP30		Epigenetic Reader Domain , Histone Acetyltransferase
	SGC-CBP30 is an effective CREBBP/EP300 inhibitor (IC50: 21/38 nM).		Epigenetic Reader Domain , Histone Acetyltransferase
T1159	Leflunomide	SU101,RS-34821,HWA486	Others , Dehydrogenase , AhR
	Leflunomide (HWA486) is an immunomodulatory agent used in the therapy of rheumatoid arthritis and psoriatic arthritis.		Others , Dehydrogenase , AhR
T38362	Guselkumab	CNTO 1959	IL Receptor
	Guselkumab (CNTO 1959) is a recombinant human IgG1 monoclonal antibody targeting the IL-23p19 subunit. Guselkumab binds to human cynomolgus monkey IL-23 with Kd values of 3.3 and 1.9 pmol/L, respectively. Guselkumab can ...		IL Receptor
T76778	Risankizumab	Risankizumab rzaa,SKYRIZI,ABBV 066,BI-655066	IL Receptor
	Risankizumab (BI 655066) is a humanized IgG monoclonal antibody (Kd <10 pM) targeting the IL-23 p19 subunit. Risankizumab inhibits IL-17 production induced by human IL-23 in mouse splenocytes with an IC50 value of 2 pM.R...		IL Receptor
T76924	Efalizumab	Hu1124,HU 1124	Integrin
	Efalizumab, a novel potent regulator of T cells, is a humanized LFA-1 α subunit (CD11a) monoclonal antibody. Efalizumab has inhibitory effects on T cell activation, skin T cell transport, and T cell adhesion to keratinoc...		Integrin
T77677	12R-LOX-IN-2		Lipoxygenase
	12R-LOX-IN-2 is an inhibitor of 12R-lipoxygenase (12R-LOX).12R-LOX-IN-2 inhibits imiquimod (IMQ)-induced hyperproliferation of psoriatic keratinocytes and inhibits colony formation.12R-LOX-IN-2 also decreases the protein...		Lipoxygenase
T21043	Apremilast, (+/-)-	Apremilast (+/-)-,
	Apremilast, (+/-)-, is a small molecule inhibitor of phosphodiesterase 4 (PDE4) with oral activity. It is used to treat psoriatic arthritis.
T76823	Perakizumab
	Perakizumab (RG4934), a humanized IgG1κ monoclonal antibody targeting IL-17A (Interleukin Related), is utilized in the study of autoimmune conditions, including psoriatic arthritis [1].
T77098	Netakimab
	Netakimab, an anti-IL-17 monoclonal antibody, is utilized in the research of ankylosing spondylitis, psoriatic arthritis, and moderate-to-severe plaque psoriasis [1] [2].
T36525	IL-17 modulator 1 disodium
	IL-17 Modulator 1 (disodium) is a potent, orally active compound, known for its high efficacy in modulating IL-17. This compound is extensively utilized for researching various diseases such as psoriasis, ankylosing spon...
T36611	(±)13-HODE
	(±)13-HODE is one of the two racemic monohydroxy fatty acids resulting from the non-enzymatic oxidation of linoleic acid. It is the principle hydroxylated fatty acid in human psoriatic skin scales, with a mean concentrat...
T76840	Vunakizumab
	Vunakizumab (Anti-Human IL17A Recombinant Antibody), a recombinant human IgGκ monoclonal antibody, specifically targets and inhibits IL-17A's interaction with its receptor, making it useful for researching autoimmune con...
T76872	Neihulizumab
	Neihulizumab (ALTB-168), an immune checkpoint agonistic antibody, targets and binds to human CD162 (PSGL-1), resulting in the downregulation of activated T-cells. It is utilized in research aimed at treating steroid-refr...
T81331	QL-1200186		JAK
	QL-1200186 is an orally active, selective TYK2 inhibitor that, upon dose-dependent oral administration, suppresses interferon-γ (IFNγ) production following interleukin-12 (IL-12) stimulation and markedly improves skin le...		JAK
T76675	Clazakizumab
	Clazakizumab, a monoclonal antibody, demonstrates high affinity and specificity towards the interleukin-6 (IL-6) cytokine, potentially inhibiting the cytokine response in COVID-19 caused by SARS-CoV-2. It is also under r...
T63558	IRAK4-IN-21
	IRAK4-IN-21 is a selective, orally active, potent IRAK4 inhibitor that acts on IRAK4 (IC50: 5 nM) and TAK1 (IC50: 56 nM). IRAK4-IN-21 exhibits potent inhibition of IL-23 production with an IC50 value of 0.17 μM. can be ...
T83457	12R-LOX-IN-1
	12R-LOX-IN-1 (Compound 4a), with an IC50 of 28.25 µM, is an inhibitor of 12R-LOX. It suppresses the hyperproliferative condition and the ability to form colonies in Imiquimod-induced psoriatic keratinocytes, as well as r...
T36379	Halometasone
	Halometasone is a synthetic corticosteroid.1,2Formulations containing halometasone have been used in the treatment of psoriasis vulgaris and eczematous dermatoses. 1.de la Brassine, M., Kint, A., Lachapelle, J.M., et al....
T63559	IRAK4-IN-22
	IRAK4-IN-22 is a selective, orally active, potent IRAK4 inhibitor that acts on IRAK4 (IC50: 3 nM) and TAK1 (IC50: 17 nM). IRAK4-IN-21 exhibits potent inhibition of IL-23 production with an IC50 value of 0.10 μM. IRAK4-IN...